Management of Bacterial and Fungal Infections in the ICU: Diagnosis, Treatment, and Prevention Recommendations
Timothy M Rawson,David B Antcliffe,Richard C Wilson,Alireza Abdolrasouli,Luke SP Moore
DOI: https://doi.org/10.2147/IDR.S390946
2023-05-04
Infection and Drug Resistance
Abstract:Timothy M Rawson, 1– 3 David B Antcliffe, 2, 4 Richard C Wilson, 1– 3 Alireza Abdolrasouli, 5 Luke SP Moore 1, 6, 7 1 Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Hammersmith Hospital, London, UK; 2 Centre for Antimicrobial Optimisation, Imperial College London, Imperial College London, London, UK; 3 David Price Evan's Group in Infectious Diseases and Global Health, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; 4 Division Anaesthesia, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Imperial College London, London, UK; 5 Department of Medical Microbiology, King's College Hospital, London, UK; 6 Chelsea & Westminster NHS Foundation Trust, London, UK; 7 North West London Pathology, Imperial College Healthcare NHS Trust, London, UK Correspondence: Timothy M Rawson, Health Protection Research Unit in Healthcare Associated Infections & Antimicrobial Resistance, Hammersmith Hospital, Du Cane Road, London, W12 0NN, United Kingdom, Email Bacterial and fungal infections are common issues for patients in the intensive care unit (ICU). Large, multinational point prevalence surveys have identified that up to 50% of ICU patients have a diagnosis of bacterial or fungal infection at any one time. Infection in the ICU is associated with its own challenges. Causative organisms often harbour intrinsic and acquired mechanisms of drug-resistance, making empiric and targeted antimicrobial selection challenging. Infection in the ICU is associated with worse clinical outcomes for patients. We review the epidemiology of bacterial and fungal infection in the ICU. We discuss risk factors for acquisition, approaches to diagnosis and management, and common strategies for the prevention of infection. Keywords: bacterial infection, fungal infection, critical care, diagnostics, therapeutics Bacterial and fungal infections are common diagnoses for patients in the intensive care unit (ICU). 1 In 2017, Vincent et al reported a 24-hour point prevalence survey of 1150 centres in 88 countries. 2 Of 15,165 patients with infection data available, 8135 (54%) had proven or suspected infection and 10,640 (70%) received at least one antimicrobial agent. Secondary infection acquired in the ICU was observed in 1760/8135 (22%). 2 Gram-negative organisms predominated (3540/5259; 67%) in those with clinically significant microbiology and fungal infection accounted for 16% (864/5259) of cases. 2 These data were similar to the previous multinational point prevalence studies, such as EPIC II that was performed in 2009 and reported that 51% of patients were considered infected, antibiotics were prescribed for 71% of patients, and Gram-negative infections accounted for 62% and fungal infections 19% of cases. 3 Mortality rates in the ICU are higher in patients with bacterial or fungal infection compared to those without infection. 2–9 In-hospital mortality for ICU patients with infection is approximately 30%. 2 Secondary bacterial or fungal infection and the presence of drug-resistant infections are independent risk factors for mortality with an increased odds of death compared to community-acquired infection (OR: 1.32; 95% CI 1.10–1.60). 2 Infections in the ICU are frequently caused by drug-resistant bacteria and increasingly drug-tolerant/resistant fungi. 3,7,10 Termed antimicrobial resistance (AMR), these infections already have a significant impact on hospitalised patients. Globally, rates of AMR will vary between regions. 11,12 Gram-negative organisms pose a major challenge including extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriales, derepressed AmpC organisms, carbapenemase-producing Enterobacteriales (CPE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa . 12 Gram-positive challenges include methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-resistant Enterococcus (GRE) species . 12 Antifungal tolerant and resistant fungal infections are an emerging threat, 13,14 not least given the high rate of associated mortality in critical care, and the relative inability to rapidly diagnose and deliver effective antimicrobial therapy. 13 Among fungal pathogens, the global emergence and spread of multidrug-resistant Candida auris has caused several healthcare-associated outbreaks. 15–17 Blood stream infections among non- albicans Candida species with decreased susceptibility to first-line antifungal -Abstract Truncated-
pharmacology & pharmacy,infectious diseases